Elevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business AchievementsPRNewsWire • 05/15/23
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PRNewsWire • 04/26/23
Elevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023PRNewsWire • 04/17/23
Elevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023PRNewsWire • 03/14/23
Elevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/09/23
Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO TransitionPRNewsWire • 01/06/23
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology SummitPRNewsWire • 11/30/22
Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 11/03/22
Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressPRNewsWire • 08/04/22
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical GroupPRNewsWire • 07/28/22
Elevation Oncology to Participate at Cowen's 3rd Annual Oncology Innovation SummitPRNewsWire • 06/01/22
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022PRNewsWire • 05/26/22
Elevation Oncology Announces FDA Fast Track Designation Granted to Seribantumab for the Tumor-Agnostic Treatment of Solid Tumors Harboring NRG1 Gene FusionsPRNewsWire • 05/25/22